{"id":"W4387809560","doi":"10.1016/j.annonc.2023.10.066","title":"LBA65 KRYSTAL-7: Efficacy and safety of adagrasib with pembrolizumab in patients with treatment-naïve, advanced non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of British Columbia","funders":"Daiichi Sankyo Europe; MSD Italia; EMD Serono; Sociedad Española de Oncología Médica; European Society for Medical Oncology; Astellas Pharma; MacroGenics; Pfizer; Incyte; BeiGene; Mirati Therapeutics; Spectrum Pharmaceuticals; Yuhan; Mersana Therapeutics; Les Laboratories Pierre Fabre; Ipsen; Array BioPharma; Jazz Pharmaceuticals; Merck KGaA; Regeneron Pharmaceuticals; AstraZeneca; Associazione Italiana di Oncologia Medica; Bristol-Myers Squibb; Ignyta; Eli Lilly and Company; American Society of Clinical Oncology; Exelixis; Sanofi; Amgen; LAM Therapeutics; Celgene","keywords":"Medicine; Discontinuation; Pembrolizumab; Adverse effect; Internal medicine; Lung cancer; Nausea; Oncology; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005530408,0.0003563105,0.0009041508,0.0002467445,0.0002099407,0.0005546231,0.0003096,0.000380041,0.001169045],"category_scores_gemma":[0.0006156564,0.000188961,0.0008196153,0.0002324828,0.0003124344,0.0006032323,0.0001861777,0.001404085,0.0003054928],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006588171,"about_ca_system_score_gemma":0.0005639282,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007505764,"about_ca_topic_score_gemma":0.002244685,"domain_scores_codex":[0.9997463,0.00007646934,0.00002168215,0.00004470339,0.00004565404,0.00006521249],"domain_scores_gemma":[0.9997765,0.00004201842,0.00005886087,0.00001697605,0.00001545408,0.00009012763],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.4995248,0.009648768,0.06699847,0.000841672,0.003466585,0.0004736675,0.00022226,0.002211387,0.05409228,0.000323458,0.002810993,0.3593857],"study_design_scores_gemma":[0.1347333,0.3213974,0.4876104,0.0002365523,0.006728646,0.002402365,0.0003102283,0.009173108,0.02381538,0.0005982622,0.0128552,0.0001391232],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9945697,0.003962513,0.00008513521,0.0001891154,0.00005735633,0.00004259345,0.0001146608,0.00003016057,0.0009487204],"genre_scores_gemma":[0.9986236,0.0006193522,0.0001001177,0.00009832068,0.00003970398,0.00002084264,0.0001832105,0.000003151742,0.0003116411],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001169045,"threshold_uncertainty_score":0.004780054,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02248700678897033,"score_gpt":0.3272610444920983,"score_spread":0.304774037703128,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}